AGILeBiotics is developing of novel antibiotics to treat multi-drug resistant (MDR) Gram-negative infections. Our main focus is to find new antibiotic candidates active against carbepenem-resistant Enterobacteriaceae (CRE) infections. In addition, AGILeBiotics is motivated in finding novel treatment options for MDR tuberculosis and cystic fibrosis.
Currently, we have two candidates, ABX506 and ABX520, in pre-clinical development, which show exceptional in vitro and in vivo activity against clinical isolates of multidrug-resistant Pseudomonas aeruginosa, Acinetobacter baumannii, and carbapenem-resistant Enterobacteriaceae.
